Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
Date:3/22/2011

ered related to Cinryze and none led to discontinuation of treatment;
  • In the open-label treatment study in which 87 laryngeal attacks occurred in 37 subjects:
    • Median time to beginning of relief of the first treated laryngeal attacks was 60 minutes, comparable to the overall median response time for attacks at all anatomic locations (45 minutes);
    • In subjects treated for more than one laryngeal attack, the effect of Cinryze was not reduced with subsequent repeated administration; median time to beginning of relief for the second and third laryngeal attacks were 30 and 38 minutes, respectively.

  • About Cinryze® (C1 esterase inhibitor [human])

    Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product that has been approved by U.S. FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.  C1 inhibitor therapy has been used acutely for more than 35 years in Europe to treat patients with C1 inhibitor deficiency.

    Severe hypersensitivity reactions to Cinryze may occur.  Thrombotic events have occurred in patients receiving Cinryze for routine prophylaxis, and in patients receiving off-label high dose C1 inhibitor therapy.  Monitor patients with known risk factors for thrombotic events.  With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.  The most common adverse reactions observed have been upper respiratory infection, sinusitis, rash and headache. No drug-related serious adverse events (SAEs) have been observed in clinical trials.

    Cinryze is for intr
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
    2. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
    3. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
    4. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
    5. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
    6. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
    7. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
    8. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
    9. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
    10. iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
    11. N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... 2014  CryoLife, Inc. (NYSE: CRY ), ... on cardiac and vascular surgery, announced today that ... Officer, has been elected to the Company,s Board of ... G. Anderson , Executive Chairman of CryoLife, stated, "Since joining ... an excellent leader who is well positioned to maximize ...
    (Date:10/22/2014)... 21, 2014   BioNano Genomics , the ... research centers to purchase an Irys™ System . ... Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) and ... obtaining a comprehensive view of a genome was ... does not deliver the scalability or reliability to ...
    (Date:10/22/2014)... 2014 Influenza will affect as many as 200,000 ... the United States as high as 49,000 people.  ... is from person to person in respiratory droplets of coughs ... of death, but kills much fewer people each year than ... human fluids including sweat, saliva, blood and other bodily fluids. ...
    Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2
    ... PARIS and TARRYTOWN, N.Y., March 10, 2011 ... ) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ... trial evaluating the investigational agent aflibercept (VEGF Trap) for ...  The data showed that adding aflibercept to the chemotherapy ...
    ... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), ... today announced that BioSpecifics, President, Tom Wegman, will present ... Stock Conference on Monday, March 14, 2011, at 11:30 ... Niguel, California. A live webcast of the ...
    Cached Medicine Technology:Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 2Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 3Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 4Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 5Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 6Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 7
    (Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
    (Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
    (Date:10/22/2014)... (HealthDay News) -- Two sisters in high school have ... Ilina and Medha Krishen use electronic stethoscopes, which electronically ... in breathing patterns or heartbeats. Ilina, a senior ... to find a way to detect early lung damage ... electronic stethoscope, Ilina recorded one breath cycle each from ...
    (Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
    (Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, ... tightened guidelines for health workers treating Ebola patients, now requiring ... a respirator at all times. The U.S. Centers for ... after two Dallas nurses contracted Ebola while caring for the ... Thomas Eric Duncan. Nina Pham is currently being treated for ...
    Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
    ... testing of 12 lymph nodes may not be as useful ... -- A new study is questioning the conventional wisdom of ... cancer surgery. , These post-op checks have been thought to ... is casting that notion in doubt. , "What we are ...
    ... of thousands of lives saved each year through immunization, ... The incidence of vaccine-preventable deaths has reached an all-time ... shows. , The study, by researchers at the U.S. ... childhood vaccinations have reduced the death rates from seven ...
    ... white paper is now,available to help hospitals prepare ... unannounced surveys at:, http://www.eheinc.com/jcaho.htm . Titled "Continuous ... Policy within the Environment of Care, and authored ... consulting firm,the white paper reviews the common barriers ...
    ... advancement in aspirin delivery ... ... out Fasprin(R), a patented, 81 milligram aspirin tablet that,dissolves rapidly in ... for the millions of Americans who maintain a,daily aspirin routine and ...
    ... than Generic Store-Brand Infant,Formulas, Says Mayo Clinic Internet Resource; Mothers ... ... Nov. 13 The Mayo Clinic, a not-for-,profit medical practice ... complex illness, now offers an online resource for,parents who choose ...
    ... Walk on November 17th will Raise Awareness and Funds ... the Homeless Capital of America, LOS ANGELES, Nov. ... that 3000 marchers have signed up to fight homelessness ... first-ever 5k,family walk called HomeWalk in Exposition Park near ...
    Cached Medicine News:Health News:Study Challenges Colon Cancer Surgery Follow-Up 2Health News:Study Challenges Colon Cancer Surgery Follow-Up 3Health News:Vaccine-Preventable Deaths Reach New Low in U.S. 2Health News:Vaccine-Preventable Deaths Reach New Low in U.S. 3Health News:Free White Paper Details Hospital Strategies for Meeting Joint Commission Compliance Requirements in the Environment of Care 2Health News:New, No-Swallow Fasprin(R) Reduces Problems Associated with Daily Aspirin Regimen 2Health News:Mayo Clinic Supports Store-Brand Infant Formulas 2Health News:United Way of Greater Los Angeles and Fannie Mae Foundation Announce 3000 Marchers for HomeWalk 2007 2Health News:United Way of Greater Los Angeles and Fannie Mae Foundation Announce 3000 Marchers for HomeWalk 2007 3
    This set is designed to introduce the low vision practitioner to the Keeler telescopic system....
    ... Featuring up to 20 ... examination in the vertical, ... plus the option to ... corneal transillumination., ,Filters include ...
    Comes complete in its own carrying case. There are 24 lenses, 13mm diameter -6D to +6D in 0.5D steps. Mounted in tough, yet light alloy frame....
    ... Interventions, like all important missions, ... guide you to your destination. ... you this dependability. So you ... the intervention and not have ...
    Medicine Products: